Intervention Review

You have free access to this content

Beta2-agonists for exercise-induced asthma

  1. Matteo Bonini1,2,3,*,
  2. Corrado Di Mambro4,
  3. Moises A Calderon3,
  4. Enrico Compalati5,
  5. Holger Schünemann6,
  6. Stephen Durham3,
  7. Giorgio W Canonica5

Editorial Group: Cochrane Airways Group

Published Online: 2 OCT 2013

Assessed as up-to-date: 13 SEP 2013

DOI: 10.1002/14651858.CD003564.pub3


How to Cite

Bonini M, Di Mambro C, Calderon MA, Compalati E, Schünemann H, Durham S, Canonica GW. Beta2-agonists for exercise-induced asthma. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD003564. DOI: 10.1002/14651858.CD003564.pub3.

Author Information

  1. 1

    "Sapienza" University, Department of Public Health and Infectious Diseases, Rome, Italy

  2. 2

    Institute of Translational Pharmacology (IFT), CNR, Rome, Italy

  3. 3

    National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, Section of Allergy and Clinical Immunology, London, UK

  4. 4

    Children's Hospital "Bambino Gesù", Department of Medical and Surgical Pediatric Cardiology - UOC Arrhythmology, Rome, Italy

  5. 5

    University of Genoa, Allergy and Respiratory Diseases Clinic, Department of Internal Medicine (DIMI), Genoa, Italy

  6. 6

    McMaster University, Departments of Clinical Epidemiology and Biostatistics and of Medicine, Hamilton, Ontario, Canada

*Matteo Bonini, Department of Public Health and Infectious Diseases, "Sapienza" University, Rome, Italy. matte.bonini@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 2 OCT 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Funnel plot of comparison: 1 Beta2-agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1.
[Figure 4]
Figure 4. Forest plot of comparison: 1 beta2-agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1.
[Figure 5]
Figure 5. Forest plot of comparison: 1 Beta2-agonists versus placebo (single administration), outcome: 1.1 Side effects.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Beta2-agonists versus placebo (single administration), outcome: 1.8 Subgroup analysis: maximal percentage fall in FEV1 SABA versus LABA.
[Figure 7]
Figure 7. Forest plot of comparison: 1 Beta2-agonists versus placebo (single administration), outcome: 1.9 Subgroup analysis: maximal percentage fall in FEV1: salmeterol versus formoterol.
[Figure 8]
Figure 8. Forest plot of comparison: 1 Beta2-agonists versus placebo (single administration), outcome: 1.10 Subgroup analysis: maximal percentage fall in FEV1: adults versus children.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 1 Maximal percentage fall in FEV1.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 2 Number of participants with an FEV1 fall > 10%.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 3 Number of participants with an FEV1 fall > 15%.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 4 Number of participants with an FEV1 fall > 20%.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 5 Maximal percentage fall in PEF.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 6 Maximal percentage fall in FEF 25-75.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 7 Side effects.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 8 Subgroup analysis: maximal percentage fall in FEV1 SABA vs LABA.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 9 Subgroup analysis: maximal percentage fall in FEV1: salmeterol versus formoterol.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Beta2-agonists versus placebo (single administration), Outcome 10 Subgroup analysis: maximal percentage fall in FEV1: adults versus children.